Skip to content
Gevokizumab
Gevokizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against interleukin-1 beta.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pyoderma gangrenosumD017511EFO_0006835L88—13——4
UveitisD014605EFO_1001231H20.9——3——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E1123———4
OsteoarthritisD010003EFO_0002506M15-M19—2——13
Type 1 diabetes mellitusD003922EFO_0001359E10—2———2
ScleritisD015423HP_0100534H15.011———1
Acne vulgarisD000152EFO_0003894L70—1———1
Behcet syndromeD001528EFO_0003780M35.211———1
Cryopyrin-associated periodic syndromesD056587M04.211———1
Rheumatoid arthritisD001172EFO_0000685M06.9—1———1
Colonic neoplasmsD003110C18—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal cell carcinomaD0022921————1
Colorectal neoplasmsD0151791————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGEVOKIZUMAB
INNgevokizumab
Description
Gevokizumab (humanized mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)GEVOKIZUMAB
Structure (InChI/SMILES or Protein Sequence)
>4G6M:H|heavy chain of gevokizumab antibody binding fragment QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQV SLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEP >4G6M:L|light chain of gevokizumab antibody binding fragment DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQ EDFATYFCLQGKMLPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE
Identifiers
PDB4G6K, 4G6M
CAS-ID1129435-60-4
RxCUI—
ChEMBL IDCHEMBL1743026
ChEBI ID—
PubChem CID—
DrugBankDB12119
UNII IDQX3JU54GYQ (ChemIDplus, GSRS)
Target
Agency Approved
IL1B
IL1B
Organism
Homo sapiens
Gene name
IL1B
Gene synonyms
IL1F2
NCBI Gene ID
3553
Protein name
interleukin-1 beta
Protein synonyms
Catabolin, IL-1 beta, interleukin 1beta, preinterleukin 1 beta, pro-interleukin-1-beta
Uniprot ID
Q9UCT6
Mouse ortholog
Il1b (16176)
interleukin-1 beta (Q2M4J6)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 430 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
9 adverse events reported
View more details